novo nordisk obesity drug - Search News

News

Novo Nordisk CEO's surprise exit

Novo Nordisk CEO's surprise exit after setbacks in weight-loss market: Reaction

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Bloomberg · 23h

Novo CEO’s Shock Exit: Who Will Take Over Obesity Drug Giant?

Novo Nordisk A/S’s surprise decision to replace Chief Executive Officer Lars Fruergaard Jorgensen has triggered a race to fill a role that is almost never available: the winner will be only its fourth leader since 1981.

Fox Business on MSN · 1d

Novo Nordisk CEO steps down as Wegovy maker faces increased competition

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

1don MSN

Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months

However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...

1don MSN

Novo Nordisk CEO's Surprise Exit After Setbacks in Weight-Loss Market

"The Novo Nordisk Foundation is increasing its influence and has appointed its chairman, Lars Rebien Sørensen, as an observer ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results